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ABSTRACT OF THE DISSERTATION 
The Genetic Basis of Susceptibility to Therapy-related Leukemia in Mice 
by 
Megan Renee Janke 
Doctor of Philosophy in Biology & Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2014
Timothy A. Graubert, Chair 
Jason Weber, Co-Chair
Treatment-related acute myeloid leukemia (t-AML) arises as a result of treating primary 
malignancies with alkylator chemotherapy drugs and has a poor prognosis.  Genetic background 
influences the risk of acquiring t-AML, yet little is known about susceptibility factors.  To 
identify candidate risk factors, cohorts of twenty inbred mouse strains were treated with N-ethyl-
N-nitrosourea (ENU), a potent alkylating agent in mice.  Six of these mouse strains were 
susceptible to alkylator-induced leukemia.  SWR/J mice were the most susceptible in this 
relatively small screen.  We expanded on that study to characterize SWR/J mice as a susceptible 
strain to t-AML using 245 mice.  Mice were treated with different permutations of steroid 
treatment to determine the effect they would have on leukemia numbers.  In addition to the 
susceptible strains, quantitative trait loci mapping was used on the initial study to identify 
genetic components responsible for the leukemic phenotype.  This analysis revealed two 
significant peaks of interest on chromosomes 3 and 14.  The 1 Mb region on chromosome 3 
contains six genes, one of which was myeloid leukemia factor 1 (Mlf1).  In humans, MLF1 was 
vii 
previously identified for its involvement in a chromosomal translocation with nucleophosmin 
(NPM) that is restricted to AML and myelodysplastic (MDS) patients.  We show that MLF1 is 
pro-apoptotic and decreases the viability of hematopoietic cells.    
viii 
CHAPTER 1 
INTRODUCTION 
1 
1.1.TREATMENT-RELATED ACUTE MYELOID LEUKEMIA 
Treatment-related acute myeloid leukemia (T-AML) is a secondary disease that arises as 
a result of initial treatment of a variety of hematologic malignancies or solid tumors with 
chemotherapy agents.  Alkylating agents represent a class of drugs that have been shown to 
contribute to this disease and are typically preceded by a therapy-related myelodysplastic 
syndrome (t-MDS) phase.  The latency of disease is 5 to 7 years following chemotherapy [1].  
Topoisomerase II inhibitors represent a second class of drugs contributing to t-AML.  The 
latency is shorter with this class of drugs and develops within 2 to 3 years following treatment[1, 
2].  Patients developing t-AML have a poorer outcome than those developing de novo AML and 
have a median survival of only 6-10 months [3].   T-AML comprises 10% of new AML patients, 
and this incidence continues to rise [4, 5].  Therefore, there is an urgent need to develop 
strategies aimed at prevention.  We are interested in identifying susceptibility genetic (inherited) 
factors for t-AML that could lead to future prevention of this disease.   
1.1.1.  POLYMORPHISMS 
There is some evidence that genetic polymorphisms influence t-AML susceptibility in 
humans, but the specific genetic factors that predispose one person to acquire t-AML over 
another is not yet known.  Candidate genes that have been studied extensively encode factors 
involved in drug detoxification pathways and DNA repair pathways. 
 DETOXIFICATION PATHWAYS 
There are two phases to drug metabolism.  Phase I involves the activation of substrates 
into intermediates.  Phase II proteins inactivate genotoxic substrates [6].  Many polymorphisms 
from these two phases have been studied in t-AML.   
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Phase I activation proteins include the cytochrome p450 (Cyp) enzymes.  These enzymes 
function in the detoxification process.  Their role is to create strong reactive intermediates that 
can cause major DNA damage unless further detoxified by Phase II enzymes[6]. 
Phase II conjunction proteins include glutathione S-transferase (GST) and NAD(P)H: 
quinone oxidoreductase NQO1. GST is from a family of isoenzymes that detoxify reactive 
electrophiles to prevent DNA damage.  NADH and NADPH catalyze the electron reduction of its 
substrates.  This prevents the formation of reactive oxygen species and free radicals that would 
lead to cellular damage [7]. 
DNA REPAIR PATHWAYS 
Mismatch repair functions as a proofreader of the DNA to avoid propogation of 
mutations.  When there is an error in which simple repetitive DNA sequences are added, stability 
is tested and microsatellite instability has formed.  Loss of MLH1 (via promoter methylation), a 
mismatch repair family member, causes microsatellite instability in t-AML patients [8, 9]. 
Double strand break repair is very damaging because of the amount of material that can 
be lost.  These types of breaks can cause cell death or chromosomal abberations.  This can occur 
after exposure to a chemotherapy drug [6].  Homologous recombination will use the intact 
chromosome as a template and will repair the damage caused by the double stranded break.  
Non-homologous end joining joins broken ends of DNA with little homology.  This is another 
way to connect the broken ends. 
The base excision repair pathway corrects one individual bases that are incorrect.  
Nucleotide excision repair removes structurally bulky damage.  It also repairs DNA damage 
caused by chemotherapy drugs.    
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1.2. Genetic Basis of t-AML Susceptibility in Mice 
Several years ago, the Graubert laboratory screened cohorts of 20 strains of inbred mice 
to determine if there was a genetic component to ENU-induced leukemia  [10].  This was a small 
screen with 12 treated and 12 untreated mice.  6 strains were susceptible and 14 were resistant.  
This demonstrated that there was a genetic component to underlying susceptibility to ENU-
induced myeloid leukemia.  SWR/J mice were the most susceptible to disease, making them a 
target for further characterization, which will be discussed in Chapter 2.  
1.3. MLF1 IS A CANDIDATE SUSCEPTIBILITY FACTOR for T-AML 
Fenske also performed quantitative trait locus mapping to accompany his research.  
MLF1 was found as a candidate by using quantitative trait locus mapping across the mouse 
genome that looked for peaks of the genome that associated with T-AML susceptibility.  6 genes 
were found within a peak on chromosome 3, and of those genes, MLF1 was the strongest based 
on the QTL results and because it was discovered as a fusion protein with NPM1-MLF1 that 
associated with t-AML/MDS (myelodysplastic syndrome).  Chapter 3 describes its function in 
hematopoietic cells.    
The purpose of this research is to 1) further characterize SWR/J mice as a susceptible 
strain and 2) understand the basic biology of MLF1 in hematopoietic cells.  This provides a 
genetic model to study t-MDS/AML.  No models are complete, so having a background where 
the mice are susceptible to disease is useful.  Breeding SWR/J mice to genetically-altered mice 
provides a powerful tool for studying t-MDS/AML.  Understanding candidate genetic factors to 
susceptibility could lead to potential therapeutics in the future.  We identified MLF1 as a 
4 
candidate susceptibility factor for t-AML.  We then went on to show the function of this protein 
in hematopoietic cells.    
5 
1.4. REFERENCES 
1. Pedersen-Bjergaard, J. and J.D. Rowley, The balanced and the unbalanced chromosome
aberrations of acute myeloid leukemia may develop in different ways and may contribute
differently to malignant transformation. Blood, 1994. 83(10): p. 2780-6.
2. Leone, G., et al., Incidence and susceptibility to therapy-related myeloid neoplasms.
Chem Biol Interact, 2010. 184(1-2): p. 39-45.
3. Larson, R.A. and M.M. Le Beau, Therapy-related myeloid leukaemia: a model for
leukemogenesis in humans. Chem Biol Interact, 2005. 153-154: p. 187-95.
4. Leone, G., et al., Therapy-related leukemia and myelodysplasia: susceptibility and
incidence. Haematologica, 2007. 92(10): p. 1389-98.
5. Leone, G., et al., Therapy related leukemias: susceptibility, prevention and treatment.
Leuk Lymphoma, 2001. 41(3-4): p. 255-76.
6. Seedhouse, C. and N. Russell, Advances in the understanding of susceptibility to
treatment-related acute myeloid leukaemia. Br J Haematol, 2007. 137(6): p. 513-29.
7. Larson, R.A., et al., Prevalence of the inactivating 609C-->T polymorphism in the
NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-
related myeloid leukemia. Blood, 1999. 94(2): p. 803-7.
8. Casorelli, I., et al., Drug treatment in the development of mismatch repair defective acute
leukemia and myelodysplastic syndrome. DNA Repair (Amst), 2003. 2(5): p. 547-59.
9. Seedhouse, C.H., E.P. Das-Gupta, and N.H. Russell, Methylation of the hMLH1 promoter
and its association with microsatellite instability in acute myeloid leukemia. Leukemia,
2003. 17(1): p. 83-8.
10. Fenske, T.S., et al., Identification of candidate alkylator-induced cancer susceptibility
genes by whole genome scanning in mice. Cancer Res, 2006. 66(10): p. 5029-38.
6 
Chapter 2 
SWR/J Mice are Susceptible to Alkylator-Induced Myeloid Leukemia 
This work is published in Blood Cancer Journal as: 
Janke, MR et al. SWR/J Mice are Susceptible to Alkylator-Induced Myeloid Leukemia. Blood 
Cancer Journal 3 (2013). 
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2.1. Results and Discussion 
Therapy-related acute myeloid leukemia (t-AML) is a late complication following 
chemotherapy and/or radiation therapy.  Approximately 10% of AML cases are therapy-related 
and the incidence is rising1.  Alkylator-associated t-AML has a latency of 5-7 years, is often 
preceded by a myelodysplastic phase (t-MDS) and is frequently associated with loss of material 
from chromosomes 5 and/or 7 in humans2, 3.  The survival of these patients is poor, motivating 
efforts to improve treatment and prevention strategies. 
It is not yet clear whether t-AML risk is influenced by host factors, or is solely a 
stochastic process.  Previous work has shown that inherited polymorphisms in drug 
detoxification (e.g.,  p450 enzymes, phase II conjugation enzymes, and 
NAD(P)H:quinoneoxidoreductase) and DNA repair (including homologous recombination and 
nucleotide excision) pathways may contribute to t-MDS/AML susceptibility, but confer only 
modestly increased risk in humans4-7. 
Alkylators (e.g., cyclophosphamide, ethyl- N-nitrosourea) are often used to generate 
cooperating mutations in genetically-engineered mouse models of leukemia8, 9.  In standard 
laboratory strains (e.g., C57BL/6J, 129Sv/J), alkylators promote thymic lymphomas efficiently, 
reducing the number of mice evaluable for myeloid neoplasms.  We previously demonstrated 
that susceptibility to alkylator-induced cancer has a genetic component in mice10.  For myeloid 
leukemia, six strains demonstrated variable degrees of susceptibility, while fourteen were 
resistant (including C57 and 129 substrains).  Of the 20 strains tested, SWR/J was the most 
susceptible.  In the current study, we evaluated a large cohort of SWR/J mice and characterized 
the phenotype of tumors induced by the prototypical alkylator, ethyl-N-nitrosourea (ENU).   
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SWR/J mice received either no treatment (‘N’ cohort, n=22), hydrocortisone (HC) alone 
(‘HC’ cohort, n=11), ENU alone (‘E’ cohort, n=27), ENU followed by HC (‘EH’ cohort, n=111), 
or HC followed by ENU (‘HE’ cohort, n=107) (see Supplementary Information).  A spectrum 
of diseases was observed, including hematopoietic tumors of both myeloid and lymphoid origins, 
and invasive lung carcinoma (Supplementary Table 1).  Lymphomas were characterized by 
infiltrating CD4+CD8+ cells (>10%) in the bone marrow or spleen, large mediastinal masses, 
and disruption of splenic architecture.  Myeloid leukemias were identified by excess myeloblasts 
(>20% of myeloid precursors) in the bone marrow or fixed tissues.  Lung cancers were grossly 
visible and were phenotyped by histologic examination. 
Of the 245 mice treated with ENU, 205 were evaluable for cancer susceptibility (40 died 
immediately after ENU injection, or were found post-mortem).  ENU treatment (with or without 
HC) resulted in 65 evaluable mice (31.7%) with lymphoma, 23 mice (11.2%) with myeloid 
leukemia, and 192 mice (92.7%) with lung carcinoma (Supplementary Table 1).  These 
diagnoses were not mutually exclusive; 5 mice had both lymphoma and myeloid leukemia, 20 
had both myeloid leukemia and lung cancer, and 61 had both lymphoma and lung cancer.  The 
lung cancer, lymphoma, and leukemia incidences in this strain differ from our previously 
published results (60%, 0%, and 80%, respectively), likely due to small cohort size in the 
previous study (n=12 ENU-treated mice)10.  Control mice developed rare lung cancers (1/22 and 
1/11 evaluable mice from the untreated and HC only groups, respectively), but no spontaneous 
hematologic cancers. 
Previous studies in mice have shown that co-administration of steroids increased the 
frequency of radiation-induced leukemias11.  To test whether steroids could increase the 
incidence of ENU-induced leukemias and reduce the competing incidence of thymic lymphoma, 
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we treated mice with HC either before or after ENU treatment.  Neither regimen decreased the 
proportion of lymphomas, nor increased the proportion of leukemias, compared to ENU alone 
(Supplementary Table 1).  It is not clear why steroids increased the incidence of radiation-
induced leukemia and had no impact on ENU-induced leukemia, but this may be attributable to 
differences in the dose, schedule of administration, or type of steroid used. 
The overall survival was significantly shorter in ENU-treated mice, compared to control 
mice (N or HC; P=0.002) (Fig. 1A).  Two mice in the control groups died with lung cancer and 
the remainder were electively sacrificed, while most of the ENU-treated mice were sacrificed 
when moribund.  For the mice treated with ENU, the median survival was longer in the EH 
cohort (331 days), compared to E or HE (290 and 291 days, respectively; P<0.0001).  The 
cumulative probability of developing lymphoma was higher than leukemia (48.4% vs. 23.9%), 
but the latency for these diseases was identical (134 days) following ENU exposure (Fig. 1B).   
Lymphomas were characterized by splenomegaly, lymphadenopathy, leukocytosis, 
anemia, and mediastinal enlargement (Supplementary Table 2, and data not shown).  The bone 
marrow was infiltrated by CD4+CD8+ cells (53.4% of cases), or single positive CD8+ cells 
(1.7% of cases) or CD4+ cells (19% of cases).  Myeloid and erythroid precursors were reduced 
in frequency (Supplementary Table 3).  Histologically, the lymphoblasts were characterized by 
open chromatin, numerous nucleoli, and vacuolization of the cytoplasm (Supplementary Fig.1). 
Myeloid leukemias were characterized by splenomegaly, leukocytosis, and accumulation 
of immature myeloid precursors in the bone marrow (Supplementary Tables 2 and 3).  The 
leukemias were uniformly Gr1+CD11b+ (Supplementary Table 2).  The myeloblasts were 
characterized by abundant cytoplasmic granulation and frequent mitotic figures (Supplementary 
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Fig. 1).  The bone marrow of 6 ENU-treated mice had significant dysplasia in the myeloid and/or 
erythroid lineages, of which 2 had myeloid leukemia, and all had significant anemia (mean 
Hb=11.3) (Supplementary Table 4).  27 additional mice (all with concurrent lung cancer) did 
not meet criteria for myeloid leukemia, but had splenomegaly and excess myeloblasts (10-15%) 
in the bone marrow.  While we favor that these bone marrow proliferations are clonal in origin, a 
reactive proliferation cannot be excluded due to the co-occurrence of a non-hematopoietic tumor. 
Tumors from two donors with myeloid leukemia were transplanted into sublethally-
irradiated congenic recipients.  All of the recipients died rapidly (3-8 weeks) after adoptive 
transfer (Fig. 2A).  Phenotypic features of the primary mice (i.e., blood counts, spleen weight, 
immunophenotype) were recapitulated in the recipients, suggesting that the leukemias were cell-
intrinsic, transplantable tumors (Fig. 2B). 
SWR/J mice developed rare spontaneous lung cancers, but hematopoietic malignancies 
were not observed in mice that did not receive ENU.  A study from 1973 reported a 37% 
incidence of lung tumors (both adenomas and adenocarcinomas) in untreated SWR/J mice12.  
Rare spontaneous lymphomas (3.6%) and myeloid leukemias (0.3%) were also observed in 
SWR/J mice followed up to 30 months in that study 12, supporting the notion that this strain has 
intrinsic susceptibility to hematopoietic malignancies.  The mechanistic basis of cancer 
susceptibility in SWR/J is not known, but it is noteworthy that a quantitative analysis of myeloid 
progenitor activity in 10 inbred strains demonstrated that SWR/J had the lowest frequency13, 
suggesting that this cellular compartment may be under proliferative stress in this strain.   
Genetically-engineered mouse models containing a single lesion detected in humans with 
myeloid leukemia may develop leukemia only after long latency or not at all, suggesting that 
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additional cooperating mutations are required.  Alkylator exposure is one strategy frequently 
used to induce secondary mutations, but this is fraught by a high incidence of competing thymic 
lymphomas, particularly in the most commonly used inbred strains (C57 and 129 substrains).  
The incidence of ENU-induced myeloid leukemia in SWR/J mice, while still modest, is higher 
than what we and others have observed in C57 and 129 substrains, suggesting that 
polymorphisms in the SWR/J genetic background predispose mice to myeloid leukemia.  
Susceptibility loci for a variety of cancers have been mapped in mice, including a Cdkn2a allele 
in lymphoid malignancies and a Ptch allele in skin cancer14, 15.  We have mapped loci associated 
with t-AML susceptibility in mice10, but the specific genes/polymorphisms responsible for this 
phenotype are not yet known.   
Therapy-related acute myeloid leukemia (t-AML) is a lethal complication arising in 
patients treated for antecedent cancers or autoimmune disorders.  Preventative strategies are 
needed, but robust predictors of susceptibility are not yet available.  Here, we show that SWR/J 
mice develop lethal, transplantable myeloid leukemias with dysplastic features after ENU 
exposure, recapitulating features of the human disease.  The SWR/J strain provides a suitable 
model for investigation of germline and somatic events that cooperate with alkylator exposure to 
cause myeloid leukemia. 
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2.3. FIGURE LEGENDS 
Figure 1.  Kaplan-Meier analysis of overall survival in ENU-treated mice.  (a) Overall survival 
was decreased in ENU-treated mice, compared to controls (P=0.002).  Administration of HC 
prior to ENU extended median and overall survival slightly, compared to ENU alone or HC after 
ENU (P<0.0001).  (b) The cumulative probability of lymphoma was higher than myeloid 
leukemia (48.4%vs.23.9%), but occurred with identical latency (134 days after ENU exposure). 
Figure 2.  ENU-induced myeloid leukemias are transplantable.  (a) Adoptive transfer of 
splenocytes from two donors with ENU-induced myeloid leukemia causes lethality with short 
latency.  (b) The spleen weight, (c) white blood cell count, and (d) hemoglobin were similar in 
donor and recipient mice.  
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2.5. SUPPLEMENTARY INFORMATION 
SWR/J Mice are Susceptible to Alkylator-Induced Myeloid Leukemia 
Megan R. Janke,1Jack D. Baty,2 Timothy A. Graubert1,3,4 
1Department of Internal Medicine, Division of Oncology, Stem Cell Biology Section, Washington 
University School of Medicine, St. Louis, MO 
2Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 
3Department of Pathology and Immunology, Washington University School of Medicine, St. 
Louis, MO 
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SUPPLEMENTARY METHODS 
Mutagenesis protocol.  SWR/J mice were obtained from Jackson Laboratory (Bar Harbor, ME) 
and housed in a pathogen-free facility.  100 mg/kg of ethyl- N-nitrosourea (ENU; Sigma-Aldrich, 
St. Louis, MO) was administered at 9 and 10 weeks of age intraperitoneally, as previously 
described1.  Some mice were given 2.5 mg hydrocortisone (HC) intraperitoneally every other 
day for 3 days one week before ENU or beginning 24 hours after the second ENU treatment.  
All procedures were approved by the Washington University Animal Studies Committee. 
Characterization of tumors.  The mice were sacrificed and analyzed when moribund or at 15 
months of age.  The lungs, mediastinal lymph nodes, thymus, and spleen were removed, 
weighed, and preserved in10% formalin.  Splenocytes were viably cryopreserved in 10% 
DMSO.  Complete blood counts were obtained using a Forcyte veterinary cell counter (Oxford 
Sciences, Inc., Oxford, CT).  Bone marrow and spleen cells were stained with conjugated 
antibodies to B220, CD3, CD45, c-kit, Gr-1, CD11b, CD34, ter119, CD4, or CD8 (BD 
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Biosciences, San Jose, CA) and analyzed by flow cytometry.  Bone marrow smears were 
stained with modified Wright-Giemsa and 200 cell differentials were performed and 
independently reviewed by a board-certified anatomic pathologist with subspecialty training in 
hematopathology.  Fixed tissues were imbedded in paraffin, sectioned, stained with H&E, then 
evaluated by a veterinary pathologist.   
Adoptive transfer.  Viably cryopreserved spleen cells from mice with myeloid leukemia were 
thawed on ice, washed in PBS, and counted.  1-2x106cells were injected via tail vein injection 
into sub-lethally irradiated (500cGy) sex-matched wildtype SWR/J recipients.  Mice were 
sacrificed when moribund.  Bone marrow, spleen, and peripheral blood cells were harvested for 
cell counts and flow cytometry.  
Statistical analysis.  Hematologic parameters were compared by one-way analyses of 
variance followed by Tukey-adjusted pairwise comparisons.    Bone-marrow morphology 
variables were first rank-transformed and then analyzed by one-way analysis of variance and 
Tukey-adjusted pairwise comparisons.  All analyses were done with SAS/STAT (ver9.3; SAS 
Institute, Cary, NC). 
SUPPLEMENTARY REFERENCES 
1. Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, et al. Identification
of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in
mice. Cancer Research 2006 May 15; 66(10): 5029-5038.
SUPPLEMENTARY FIGURE LEGEND 
Supplementary Figure 1.  Morphology of hematopoietic tumors in ENU-treated mice.  
(a,d,g) Bone marrow, (b,e,h) peripheral blood, and (c,f,i) spleen cells from (a-c) ENU-treated 
SWR/J mice with no pathology, (d-f) myeloid leukemia, and (g-i) lymphoma. 
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CHAPTER 3 
MLF1 IS A CANDIDATE SUSCEPTIBILITY FACTOR FOR T-AML 
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3.1. INTRODUCTION 
Several years ago, the Graubert laboratory  used an inbred mouse screen to identify novel 
risk factors for t-AML[1].  This allowed us to control for environmental factors and test the 
effect of different genetic backgrounds.  Cohorts of 20 inbred mouse strains were treated with 
ENU, a potent mutagen in mice, and observed for incidence of myeloid leukemia.  Strains were 
classified as being susceptible or resistant to acquiring alkylator-induced t-AML.  Quantitative 
trait locus mapping was used to identify candidate susceptibility factors.   
Treating the mice with ENU resulted in 6 susceptible stains that had a myeloid cancer 
incidence which ranged between 18 and 80%.  The other 14 strains were resistant.  The 
difference in cancer incidence between the strains suggests that there is genetic component 
contributing to susceptibility.  
A genome wide association study was used to identify any regions that contributed to 
myeloid leukemia.  One peak on chromosome 3 exceeded the significant threshold at a genome 
wide level.  The 1.07 Mb region associated with that peak contained six genes (Shox2, Rsrc1, 
Mlf1, Gfm1, Lxn, Rarres 1) (Figure 3.1).  Of these genes, myeloid leukemia factor 1 (Mlf1) was 
chosen as the strongest susceptibility factor based on the results of the QTL mapping and 
previous findings of its involvement in a chromosomal translocation found in AML patients.   
3.1.1. GENES IN PEAK ON CHROMOSOME 3 
Shox2 
Short stature homeobox 2 (Shox2) is a member of the homeobox family of genes.  Shox2 
has been shown to be hypermethylated in lung cancer patients.  This correlated with gene 
amplification in lung cancer tissue [2]. 
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Rsrc1 
Arginine/serine-rich coiled-coil 1 (Rsrc1) is a member of the arginine and serine rich-
related protein family.  Rsrc1 affects m-RNA splicing  [3].  The protein typically functions early 
in sliceosome formation [4]. 
Gfm1 
G elongation factor, mitochondrial 1 (Gfm1) encodes a mitochondrial elongation factor 
important for mitochondrial translation.  Without normal translation of the respiratory system, 
there is a reduction of oxidative reduction that can underlie disease [5]. 
Lxn 
Latexin (Lxn) influences size of hematopoietic stem cell populations [6].  Highest 
expression was found in lin- cells and overexpression assays showed a decrease in stem cell 
population size.  Lxn is also the only known protein inhibitor of zinc-dependent 
metallocarboxypeptidases [7]. 
Rarres 1 
Retinoic acid receptor responder (tazarotene induced) 1 is a retinoid acid (RA) receptor-
responsive gene that encodes a type 1 membrane protein.  Hypermethylation of the promoter 
downregulates RARRES1 expression in several cancers, including prostate cancer [8].   
Mlf1 
The nucleophosmin (NPM1)-MLF1 fusion protein is how MLF1 was first identified.  The 
fusion protein is associated with MDS and AML patients, which in combination with the QTL 
results made MLF1 the strongest risk factor to explore.    
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3.1.2. MLF1 
MLF1 encodes 267 amino acids, corresponding with a 31 kDa protein [9].  Evidence 
suggests it is an oncoprotein [9].  There is no known homology with other characterized proteins 
to hint at the normal function of wildtype MLF1.  Several groups, including ourselves, have 
sought to understand the normal biology of the protein.   
3.1.3. FUNCTION 
Williams et al. show that MLF1 is activated during during erythroid to myeloid switching 
[10].  They used J2E erythroleukemic cells to show that MLF1 expression could switch it to a 
monocytoid phenotype.  Overall they show that MLF1 expression favors myeloid differentiation 
and impedes the erythropoietic pathway.  Dysregulation could account for increased 
erythroleukemias.  This is also true of MLF1 interacting protein (MLF1IP).  MLF1IP may have 
its expression confined to the erythroid lineage.     
One model for how Mlf1 might function involves Madm and Manp regulating the 
shuttling of Mlf1 between the nucleus and the cytoplasm [11].  Madm recruits a serine to Mlf1 so 
14-3-3ζ will bind and sequester Mlf1 in the cytoplasm.  When Mlf1 is not bound, it can shuttle 
into the nucleus where it binds Manp and DNA.  Mlf1 acts as a gene expression regulator.  
One gene that MLF1 regulates is p53 by suppressing COP1 via COP9 subunit 3 (CSN3).  
Both stress and overexpression of MLF1 lead to binding of CSN3 and a decreased level of COP1 
[12].  COP1 is an E3 ubiquitin ligase for p53.  Those signals lead to increased levels of p53.  The 
final step leads to cell cycle arrest. 
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3.1.4. EXPRESSION  
 MLF1 is expressed in a variety of tissues.  Two transcripts get expressed in tissues, the 
most commonly expressed is 1.7 kb and the other is 2.5 kb.  Highest MLF1 mRNA was found in 
testis and lowest in spleen, thymus and peripheral blood [9].  Normal human MLF1 is expressed 
in CD34+ cells.  In the Washington University de novo AML patient samples, MLF1 expression 
was low in all patient samples, as well as in the CD34+ cells (Figure 3.2).    
 Matsumoto et al. used RNA from AML and MDS patient samples to show that MLF1 is 
not expressed in peripheral blood, normal bone marrow, or in ALL patients, but that it is 
expressed in varying degrees across the subtypes of AML [13].  In addition, they show that 
patients with a prior MDS phase have increased MLF1 expression.   
3.1.5. BINDING PARTNERS 
Lim et al. identified the novel MLF1-adaptor molecule (Madm) and 14-3-3ζ as binding 
partners of wildtype MLF1 by performing yeast two-hybrids [14].  14-3-3 (RSXSXP) motifs are 
important binding sites for many binding partners involved with important processes such as cell 
death, cell differentiation, and cell division [15-17].  The binding of 14-3-3ζ is thought to 
sequester Mlf1 in the cytoplasm [14].  Madm co-localizes with Mlf1.  Madm recruits a serine 
kinase that activates the 14-3-3 binding motif of Mlf1.  This is thought to keep Mlf1 in the 
cytoplasm and affects the ability of cells to differentiate.           
MLF1-interacting protein (MLF1IP) is a novel protein identified by a yeast two-hybrid 
screen and confirmed by pulldown assays [18].  MLF1IP and MLF1 tend to colocalize and 
associate with one another.  They have similar tissue distributions, MLF1IP having especially 
high expression in the hematopoietic organs.  It is expressed in erythroblasts but not 
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differentiated erythrocytes.  This suggests a potential role for deregulation of MLF1IP or MLF1 
in erythroleukemias. 
Yonedo-Kato et al. identified COP9 subunit 3 (CSN3) as a binding partner of MLF1 [12].  
The binding of MLF1 and CSN3 leads to downregulation of COP1 which regulates p53.  This is 
another important binding partner that gives a novel function of MLF1. 
Mlf1-associated nuclear protein (Manp) is homologous to a heterogeneous nuclear 
ribonucleoprotein U-like molecule (hnRNP-U) and contains a DNA-binding domain [11].  Mlf1 
and Manp colocalize in the nucleus, and Mlf1 is capable of binding DNA.  Winteringham et al. 
also suggest that Mlf1 has a nuclear export signal.   
3.1.6. FUSION PROTEINS 
Nucleophosmin is a nucleolar phosphoprotein that is involved in ribosomal biogenesis, 
modulating tumor suppressors p53 and Arf, and is upregulted in response to DNA damage [19-
21].  It shuttles between the nucleus and the cytoplasm [22].  Npm1 acts as a haploinsufficient 
tumor suppressor gene [23].   In addition, NPMI is the most frequently mutated gene in AML, 
with 35% being mutated in AML patients [24].  It is involved in translocations in which varying 
lengths of NPM1 fuse with MLF1, RARα, or ALK [25].  The fusion partner determines the 
disease and thus can be used as a diagnostic tool.   
NPM-MLF1 is a rare chromosomal translocation t(3;5)(q25;q35) that occurs in less than 
1% of AML cases and is associated with MDS [9].  175 of 294 amino acids of NPM1 fuse with 
almost all of MLF1 (252 of 268 amino acids)(Figure 3.3).  Importantly, NPM1 conserves more 
of its functional domains in the NPM1-MLF1 fusion than any of its other fusion partners [9].  
One characteristic of this fusion is aberrant expression of MLF1 in the nucleus and NPM in the 
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cytoplasm.  It also causes overexpression of MLF1 in hematopoietic cells where expression is 
generally low [25].  Ectopic expression of the fusion in cell lines induces apoptosis [26]. 
NPM-ALK forms the t(2;5)(p23;q35) translocation found in 85% of ALK+ anaplastic 
large cell lymphoma (ALCL) [27].   Oligomerization of the oncogenic fusion protein leads to 
constitutive activation of the kinase ALK [28].  NPM-ALK, like NPM-MLF1, gets mislocalized 
to the nucleus, although this is not required for lymphomagenesis.     
NPM- RARα is a rare t(5;17) chromosomal translocation involved with acute 
promyelocytic  leukemia.  The fusion protein interacts with wildtype NPM1 by mislocalizing it 
or altering its function in the nucleolus [29].   NPM- RARα disrupts the retinoid-responsive gene 
expression and arrests myeloid differentiation at the promyelocyte stage by regulating the 
retinoid-responsive gene expression [30].  
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3.2. RESULTS 
MLF1 was first identified as a partner in a fusion protein (NPM-MLF1) associated with 
AML/MDS.  We found MLF1 using QTL mapping that identified regions in the mouse genome 
that associated with susceptibility to t-AML.  The function of MLF1 on hematopoietic cells had 
never been explored.  Expression of MLF1 is low in hematopoietic cells, but is higher in AML 
patients and highest in patients with a prior MDS phase.  In addition, MLF1 is expressed higher 
in the more primitive CD34+ bone marrow cells.  Together, this suggests that MLF1 could affect 
leukemogenesis.  That led us to hypothesize that the dysregulation of MLF1 expression is 
relevant for the initiation of alkylator induced t-AML.  The aims of this project were to:  1) 
determine the in vitro molecular consequences of MLF1 overexpression on hematopoietic cells, 
2) determine the functional consequences of MLF1 overexpression in vivo, and 3) determine the
relevance of Mlf1 on the initiation of alkylator induced leukemia. 
3.2.1. OVEREXPRESSION IN VITRO 
3.2.2. OVEREXPRESSION OF MLF1-IRES-YFP-MSCV IN Ba/F3 CELLS 
To address how different levels of Mlf1 expression might affect t-AML susceptibility, we 
used an in vitro overexpression assay in the pro-B cell Ba/F3 cell line.  Ba/F3 cells are IL-3 
dependent and thus can be sensitized to apoptosis by the removal of IL-3 from the medium.  
Approximately 13% of cells were transduced with the MLF1-ires-YFP-MSCV retrovirus, while 
28% of the cells were transduced with the control vector (Figure 3.4).  Cells overexpressing the 
YFP-MSCV control retrovirus expanded nearly 3-fold times more than those overexpressing the 
MLF1-ires-YFP-MSCV retrovirus at 48 and 72 hours following infection (Figure 3.5 b,c,d).  To 
investigate whether this was a result of increased apoptosis, we stained cells with the apoptotic 
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markers Annexin V and 7-Amino-actinomycin D (7-AAD) and analyzed by flow cytometry.  We 
found that there was 6-fold more death in cells overexpressing MLF1 in comparison to the 
control empty vector (33% in MLF-IRES- YFP vs. 5% in control; p<0.0001) (Figure 3.6).    
3.2.3. METHODS 
Full length human MLF1 cDNA was cloned into the multiple cloning site of the murine 
stem cell virus (MSCV) vector that contains an ires-YFP.  293T packaging cells were transfected 
with either MLF1- ires- YFP-MSCV or control YFP-MSCV vector to yield replication-
incompetent retrovirus.   Ba/F3 cells were transduced with either an MLF1-ires-YFP-MSCV 
retrovirus or control YFP-MSCV retrovirus with similar multiplicities of infection.  The virus 
was removed after 3, 6, 12, or 24 hours of exposure and cells were replated with identical cell 
densities in RPMI medium containing different concentrations of IL-3 ranging from insufficient 
for cell growth (0ng/mL) to sufficient (5ng/mL).  At 24, 48, and 72 hours post viral exposure, we 
analyzed cell growth and viability.  Trypan blue staining was used to determine cell viability, 
while flow cytometry was used to determine the percentage of cells overexpressing each virus by 
gating on YFP+ cells. 
3.2.4. OVEREXPRESSION OF MLF1-IRES-YFP-MSCV IN PRIMARY BONE 
MARROW CELLS  
Initial studies were performed in Ba/F3 cells because they are hematopoietic, easily 
transduced, and provide an easily manipulated system in which to study the effects of MLF1 
overexpression.  The next step was to analyze the effects of MLF1 overexpression in primary 
bone marrow cells.   This was more challenging than studies in cell lines because heterogeneity 
of the population and lower transduction efficiencies.  
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Results show that cells overexpressing MLF1-ires-YFP-MSCV have impaired growth in 
comparison to cells infected with the control virus (YFP-MSCV)(Figure 3.7).  We show that this 
impaired growth is due to, at least in part, increased apoptosis.  At 24 hours, cells overexpressing 
MLF1 had a significantly higher percentage of apoptosis than those overexpressing the control 
retrovirus (p<0.001) (Figure 3.7).  At 48 hours there was no significant difference in apoptosis 
between the two groups. These results suggest that MLF1 is playing a role in inducing apoptosis 
in primary hematopoietic cells.  
3.2.5. METHODS 
We harvested bone marrow from 2 femurs and 2 tibias from a C57BL/6J mouse age 6-8 
weeks and transduced bulk bone marrow cells with either MLF1-IRES-YFP-MSCV retrovirus or 
control YFP-MSCV with similar multiplicities of infection.  Cell viability and apoptosis status 
was determined as described above.   
3.2.6 TRANSGENIC 
Vav was used as the promoter for making a HA-hMLF1 transgenic mouse because of its 
exclusive pan-hematopoietic expression and modest expression in cells (Ogilvy 1999 Blood).  
Vav acts by transducing signals from surface receptors to Rho-like G proteins (Crespo, Nature 
1997).  The HA tag was to allow us to easily analyze a variety of tissues for the presence of the 
tagged protein.  We cloned HA-tagged human MLF1 into the HS321/45 vav vector (Figure 3.8).  
HA, MLF1, and GFP protein were all detected by Western blots when transduced into NIH3T3s 
(Figures 3.9).  In addition to sequencing, this confirmed that the correct constructs were made.  3 
founder lines were identified out of the 43 possible clones that expressed the transgene at high, 
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medium, and relatively low levels.  The founder mice were all males and were bred extensively, 
but no transgene positive progeny were identified.  
3.2.7 METHODS 
Human MLF1 was shuttled into vector topo2.1 (Invitrogen).  The HA tag was added in 
frame to the 5’ end of hMLF1.  This was confirmed via sequencing.  Next, HA-tagged human 
MLF1 was cloned into the HS321/45 vav vector.  This vector was confirmed by sequencing and 
by the expression of the correct proteins (HA, MLF1, GFP) when transduced into the NIH3T3 
cell line.   
To prepare the DNA for pronuclear microinjection, we first purified the plasmid (Qiagen 
Endo-Free Plasmid Maxi Kit).  Then the vector backbone was removed in a restriction digest.  
The insert was separated from the vector on a 0.8% agarose gel and using a QIAquick PCR 
purification kit (Qiagen).  Recovered DNA was at a concentration of 30ng/uL in microinjection 
buffer.  The vav-HA-hMLF1 construct was injected into FVB/N eggs to generate founder lines.   
43 clones were tested by Southern blots to determine if they carried the transgene.  
Briefly, the clones were digested with an enzyme restriction and then run out on a gel.  From 
there, the gel contents were transferred to a membrane where it was then probed with a radio-
labelled single-stranded piece of DNA, hybridized, and analyzed by autoradiography.  Then the 
probe was detected by putting the membrane through the X-Ray machine.       
3.2.8 DISCUSSION 
Overexpression of MLF1-ires-YFP in Ba/F3 cells and primary bone marrow cells led to 
decreased viability due to, at least in part, increased apoptosis.  This is consistent with the 
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literature which suggested a pro-apoptotic role for MLF1 in NIH3T3s.  We wanted to know the 
function of MLF1 in hematopoietic cells.   We also wanted to know what overexpression of 
MLF1 would look like in a transgenic mouse.  We chose to use the vav promoter which drives 
expression in hematopoietic cells.  Clones were verified by southerns, but no pups were born 
from our founders.  This is likely due to male infertility caused by the overexpression of a pro-
apoptotic factor.  Alternative methods such as a conditional mouse must be considered to make a 
viable mouse. 
3.2.9 RELEVANCE OF MLF1 ON ENU-INDUCED LEUKEMIA AND STRESS 
We wanted to determine if Mlf1 expression levels affected the response of bone marrow 
cells to treatment with the alkylating agent ENU.   These sets of experiments were to understand 
whether Mlf1 was important following a potent mutagen treatment or stress condition.  We 
hypothesized the dysregulation of Mlf1 would affect the cellular response to these stressors and 
contribute to disease.  
3.2.10 RELEVANCE OF MLF1 FOLLOWING IN VITRO ENU TREATMENT 
 Bone marrow was harvested from wildtype C57BL/6J mice and from fully backcrossed 
Mlf1 knockout mice.  24 hours later the bone marrow cells were treated with ENU for 1 hour.  
After 16 hours the cells were analyzed by FACS using the myeloid lineage marker Gr-1 and 
Annexin V.  There was a trend toward increase in the percentage of apoptotic cells in the 
wildtype mice between the untreated and treated cells (p=0.101), whereas there was no 
significant difference between untreated and treated Mlf1 -/- bone marrow cells (Figure 3.10a).  
In another experiment, the same phenotype was seen using bulk bone marrow (Figure 3.10b).  
This suggests that Mlf1 is required for an apoptotic response to ENU. 
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Bone marrow was harvested from fully backcrossed Mlf1 wildtype, heterozygous, and 
knockout SWR/J mice and flow sorted for kit+lin- cells.  After 24 hours the bone marrow was 
treated for one hour with ENU and then analyzed at 24 and 48 hours later.  At 48 hours, there 
was a significant growth impairment between the wildtype and knockout cells (p<0.0001) 
(Figure 3.11a).  There was increased cell death seen in all genotypes, especially in the wildtype 
cells, although this was not significantly more than the others (Figure 3.11b). 
3.2.11 METHODS 
Mlf1 null mice were generated and provided to us by the Steve Morris lab (unpublished).  
Briefly, a targeted strategy was utilized to disrupt Mlf1 expression by replacing a portion of exon 
2 with a Neo cassette which results in translational stops.  We fully backcrossed Mlf1 null mice 
to both C57BL/6J and SWR/J backgrounds which represent a strain that is resistant to myeloid 
leukemias (C57BL/6J) and susceptible (SWR/J).  Speed congenics confirmed greater than 98% 
purity of the strains.  Genotypes were identified by PCR.  Bone marrow was flushed from 2 
tibias and 2 femurs from mice wildtype, heterozygous, or null for the Mlf1 allele 
(N=3/genotype).  Unsorted bone marrow was cultured and treated with a range of doses of ENU 
or DMSO vehicle control.  We analyzed the cells for apoptosis by flow cytometry at different 
time points up to 72 hours following treatment.  Gr-1+ cells were marked to determine if there is 
a compartment specific response to ENU-induced apoptosis due to loss of Mlf1. 
3.2.12 RESPONSE OF MLF1 GENOTYPES FOLLOWING STRESS 
Mlf1-/-,+/-,+/+ C57BL/6J mice were sub-lethally irradiated to determine if lacking Mlf1 
protects those cells from undergoing cell death and thus recover quicker in response to stress.  
Complete blood counts were obtained through eye bleeds six times from day 0 to day 28.  Each 
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genotype hit nadir around 6 days as expected.  There was no significant change in genotype 
recovery in white blood cells, neutrophils, hemoglobin, lymphocytes, platelets, or monocytes 
(Figure 3.12). 
3.2.13 METHODS 
Mlf1-/-,+/-,+/+ C57BL/6J (3 mice/genotype) ages 6-8 weeks first received eye bleeds and 
complete blood cell counts were conducted.  The same day they were treated with a sub-lethal 
dose (500 RADs) of radiation using a gamma irradiator.  Mice were kept in a pathogen-free 
facility for 28 days.  They received an additional 4 more eye bleeds throughout the 28 days.  This 
allowed for complete blood cell counts to monitor recovery following the stress.  On the 28th day 
following irradiation, the mice were sacrificed and a heart stick was performed for the final time 
point. 
3.2.14 DISCUSSION 
MLF1 does influence how many cells undergo ENU-induced apoptosis.  There was a 
significant difference between MLF-/- vs MLF1+/+ mice when comparing ENU-induced cell 
death.  There was no significant difference between knockout cells.  This is the expected result.  
We have now shown that MLF1 is pro-apoptotic in vitro and in vivo under overexpression and 
stress conditions.  There is still cell death occurring in the knockout cells.  This tells us that 
MLF1 contributes to the apoptotic response, but is not essential. 
When we observed recovery following sub-lethal irradiation, we did not see a difference 
between the MLF1 genotypes in recovery time.  We thought that the knockout might have an 
advantage gained from the protection it gets from surviving the initial stress.  It could be that at 
the dose we gave the mice, it is too high and acts as an equalizer.  You could play with doses 
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until you found a dose that shows a difference, but 500 RADS of irradiation.  A more detailed 
analysis across a range of radiation doses may reveal a role for MLF1 in hematopoietic recovery 
following sub-lethal irradiation. 
3.2.15 RELEVANCE OF MLF1 ON ENU-INDUCED LEUKEMIA 
Loss or gain of pro-apoptotic Mlf1 within the bone marrow may impact whether a cell 
undergoes apoptosis in response to ENU treatment, or if cells persist and acquire mutations that 
contribute to disease (Figure 3.13).  We hypothesized that the dysregulation of MLF1 expression 
contribute to disease.  To test this, 10 wildtype, 18 heterozygous, and 11 knockout C57BL/6J 
mice were treated in vivo with ENU.  They were sacrificed when moribund and analyzed for 
myeloid malignancies, lymphomas, and lung cancers.  Each disease was identified as described 
in chapter 2. 
Overall survival was not significantly different between the genotypes (Figure 3.14).  The 
median survival for knockout mice was 307 days.  Wildtype and heterozygous mice had nearly 
identical median survivals with 258 and 256 days, respectively.  
Briefly, lymphomas were characterized by splenomegaly, enlarged mediastinal mass, 
leukocytosis, and anemia (Tables 2 and 3a,b,c).  Knockout mice had 0% cases of greater than 
10% CD4+CD8+ infiltration in the bone marrow, heterozygous mice had 11.8% cases double 
positive, and wildtype and 14.3% of cases.  Wildtype mice had the greatest percentage of 
lymphomas with 57.1% being positive (Table 1).  With that said, three of those cases involve 
concurrent lymphomas which were counted as both diseases. 
Myeloid leukemias were characterized by splenomegaly, leukocytosis, and accumulation 
of immature myeloid precursors as called by a veterinary pathologist (Tables 2 and 3a,b,c).  Only 
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3 wildtype mice developed leukemia, which were confirmed by a pathologist.  This was in 
addition to the lymphoma and the lung cancer that they also developed.  They were all 
Gr1+CD11b+. 
3.2.16 METHODS 
We used genetically defined mice for Mlf1 loss on the C57BL/6J backgrounds described 
above.  A cohort of at least 10 mice per genotype were intraperitoneally injected with 2 doses 
(100mg/kg) of ENU at 9 and 10 weeks of age.  The mice were observed for up to 16 months and 
sacrificed when moribund.  Mice were analyzed for the presence of myeloid malignancy, 
lymphomas, and lung cancers.  Complete blood cell counts were determined by an automated 
cell counter.  Bone marrow and peripheral blood were stained for flow cytometric analysis with 
antibodies conjugated to B220, CD3, CD45, c-Kit, CD11b, Gr-1, ter119, and Dx5.  Tissues were 
fixed in 10% formalin for analysis by a veterinary pathologist.  Survival curves were determined 
using the Kaplan-Meier method. 
3.2.17 DISCUSSION  
The only mice to get leukemia were the Mlf1 wildtype mice and these were concurrent 
with lymphomas.  We had predicted that the knockout mice would be the ones to persist and 
acquire mutations that would lead to leukemia.  Instead the knockout mice developed 
lymphomas and lung cancers at a high rate and died of that instead.  Lymphomas do have a 
shortened latency compared to the other diseases.  These experiments were performed in 
C57BL/6J background, which is predisposed to develop lymphomas because of retroviruses.  
You might see a different result if you tested a genetic background resistant to lymphomas, or if 
you bred in a transgene that sensitizes to development of leukemia (e.g. PML/RARA). 
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3.3. SUMMARY  
Results from Ba/F3 cells indicate that YFP+ cells infected with the control virus 
expanded to nearly 3-fold greater levels than cells overexpressing MLF1 when analyzed at 48 
and 72 hours under sufficient IL-3 conditions (Figure 3.5).  We show that the decreased 
accumulation of MLF1-expressing cells is due to, at least in part, a 6-fold increase in apoptosis  
(33% in MLF-IRES- YFP vs. 5% in control)(Figure 3.6).Overexpression of MLF1 in primary 
hematopoietic cells also led to decreased accumulation of those cells.  It was partly due to the 
increase in apoptosis, especially at 24 hours.  The MLF1 transgenic was not viable.   Constitutive 
activation of MLF1 may cause male infertility issues, or cause developmental problems that 
cannot be overcome.   
ENU induced a significant amount of apoptosis in vitro between C57BL/6J MLF1 
wildtype and knockout bone marrow cells.  There was no significant response between knockout 
cells, suggesting that MLF1 is playing a role in apoptosis.  SWR/J mice sorted for kit+/lin- cells 
before they were treated, and at 48 hours there was a significant difference between the wildtype 
and knockout cell growth and viability.  When Mlf1 C57BL/6J mice of varying genotypes were 
sub-lethally irradiated to determine the effect on recovery post stress, we saw no significant 
difference between the genotypes.  This was a little surprising given that Mlf1 had been shown to 
be significant when presented with the genotoxic stressor ENU. 
Unexpectedly, Mlf1 wildtype mice developed the leukemias instead of the knockouts.  
This suggests that perhaps in this small study, the knockouts did persist when treated with ENU, 
but developed the fast growing lymphomas instead.  Although, it is highly unlikely that 30% of 
mice get leukemia and we have shown that they do not with larger cohort sizes.  Every cell in the 
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body is being affected by this treatment.  Transplants might be the only way to get a true answer 
to what effect Mlf1 has on the mice in vivo.      
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3.4. FIGURE LEGENDS 
3.1 Genomic locus associated with susceptibility to ENU-induced myeloid leukemia.  A 
genome-wide association study was performed across the entire mouse genome to identify 
peaks that associated with the phenotype of susceptibility to ENU-induced myeloid leukemia.  A 
peak on Chromosome 3 did exceed the threshold and within the 1 Mb region lies 6 genes.   
Horizontal line is a false discovery threshold of 10%. 
3.2 MLF1 expression in Washington University de novo AML patient samples.  3 MLF1 probes 
were used on de novo AML patients to determine expression in hematopoietic cells.  7 patients 
had very low expression of MLF1.  Expression was also low in CD34+, Pros, and PMNs.       
3.3 Structural and functional domains of the MLF1-NPM1 fusion protein and wildtype NPM1.  
NPM1-MLF1 fusion constitutes the N-terminus of NPM1 (amino acids 1-175) and almost the 
entire MLF1 protein, excluding the first 16 N-terminus amino acids.  The fusion retains the 
NPM1 metal binding domain (MB), one complete acidic amino acid cluster (AC), and one of the 
nuclear localization signals (N).  MLF1 retains a 14-3-3 binding site, two nuclear localization 
signals, and nuclear export signal. 
3.4 IL-3 dependent Ba/F3 cells were transduced with either an MLF1 ires YFP-MSCV retrovirus 
or control YFP-MSCV retrovirus with similar multiplicities of infection.  Cells were kept in RPMI 
and 5ng/mL IL-3.  After 24 hours, cells were analyzed by flow cytometry to determine percent 
transduced using YFP as a marker.  Cells transfected with the control MSCV-YFP retrovirus had 
2-fold more YFP+ cells than those transduced with the MLF1-MSCV retrovirus.  
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3.5 MLF1-MSCV infected Ba/F3 cells have growth impairment.  The MLF1-MSCV and empty 
retrovirus were removed after 12 hours and cells were replated in RPMI containing different 
concentrations of IL-3 ranging from insufficient for cell growth (0ng/mL) to sufficient (5ng/mL). 
a) Cells in IL-3 concentration insufficient for cell growth did not expand.  b,c,d) YFP+ cells
infected with the control virus expanded to nearly 3-fold greater levels than cells 
overexpressing MLF1 when analyzed at 48 and 72 hours under sufficient conditions.  
3.6 There is a decreased accumulation of MLF1-expressing cells is due to, at least in part, a 6-
fold increase in apoptosis (33% in MLF ires YFP vs. 5% in control).  Ba/F3 cells transduced by 
either MLF1-MSCV or YFP-MSCV control in different concentrations of IL-3 at a) 24 and b) 48 
hours showed increased apoptosis.   Cells overexpressing MLF1 at 24 hours in 0ng/mL IL-3 had a 
6-fold increase in death.  N=>5 times     
3.7 Bone marrow cells transfected with MLF1-MSCV retrovirus have cell growth impairment. 
Wildtype C57BL/6J bone marrow was harvested and transfected with MLF1-MSCV retrovirus or 
the empty vector.  a) At 24, 48, and 72 hours post-transfection, live and dead cells were 
counted using a hemocytometer and trypan blue staining to show decreased cell growth with 
cells transfected with MLF1-MSCV.  b) Flow cytometry was used to determine percentage of 
transfected cells with MLF1-ires-YFP using YFP as the marker.  Annexin V was used as the 
marker for cell death and showed that the growth impairment was due to a significant increase 
in apoptosis at 24 hours. 
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3.8 vav-HA-hMLF1 Transgene.  a) Schematic of the transgene showing the position of the 
promoter, HA, hMLF1, and the probe location used for southerns.  b) Schematic of the HA-
MLF1-ires-YFP retrovirus. 
3.9 Plasmids vav-HA-MLF1 and HA-MLFI-IRES-YFP-MSCV express both HA and overexpress 
MLF1.  Vav as a promoter has the ability to drive a moderate level of overexpression.  a) 
Untransfected and vav-HA-MLF1 transfected 3T3 cells lack YFP therefore do not express protein 
detected by the GFP anibody as expected.  This proves the backbone has been removed in the 
making of the vav-HA-MLF1 plasmid.  In contrast, HA-MLFI-IRES-YFP-MSCV still contains YFP 
and is detectable by the GFP protein. b,c) vav-HA-MLF1 and HA-MLFI-IRES-YFP-MSCV both 
contain HA and MLF1. 
3.10 ENU treatment results in significant death of wildtype C57BL/6J bone marrow cells. Bone 
marrow was harvested from C57BL/6J mice and analyzed by flow cytometry.  a) There was a 
significant difference (p=0.0101) in Gr-1 wildtype C57BL/6J bone marrow cells that were 
apoptotic.  There was no significant difference in the MLF1-/- mice. N/3 mice per genotype. b) 
The same phenotype was seen in bulk bone marrow cells.  There was no significant difference 
between treated knockouts, but there was significance between wildtypes.  N>5 
3.11 SWR/J Mlf1-/- mice are significantly more viable than Mlf1+/+ when treated with ENU.  
SWR/J bone marrow was harvested from genetically defined mice and sorted for kit+lin- cells.  
Cells were treated for 1 hour with ENU and left for 24 hours before being analyzed by flow 
cytometry  a)  Trypan blue staining was used to determine viablility of SWR/J Mlf1-/-,+/-,+/+.  b)  
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This was, in part, due to increased apoptosis.  FACS marker Annexin V was used to determine 
cell death.  N>2 
3.12 There was no significant difference in recovery between C57BL/6J MLF1+/+,+/-,-/- mice 
following sublethal irradiation.  3 mice from each C57BL/6J MLF1+/+,+/-,-/- genotype were 
sublethally irradiated (500 RADs) using a gamma irradiator.  They each received 6 eye bleeds for 
CBCs between days 0 and 28.  Recovery was monitored to determine if MLF1 provided an 
advantage or disadvantage to the mice following a stress.   
3.13 Model of MLF1 contribution to leukemia.  We and others have shown that MLF1 is a pro-
apoptotic protein, expressed in early myeloid progenitors, the cellular compartment relevant 
for leukemogenesis.  We hypothesize that the expression levels of MLF1 may be one 
determinant that influences whether or not cells exposed to genotoxic chemotherapy agents 
undergo apoptosis.  In this model, cells with relatively high levels of MLF1 are poised to 
undergo apoptosis, whereas cells with lower levels would be more likely to persist, accumulate 
mutations, and contribute to leukemias. 
3.14 Kaplan–Meier analysis of overall survival in ENU-treated C57BL/6J Mlf1-/-,+/-,+/+ mice. 
C57BL/6J mice of defined genetic backgrounds were treated with ENU and observed until 
moribund.  Overall survival was not significantly different in the ENU-treated mice.  The 
knockouts had a slightly shorter median than the heterozygous and the wildtypes (307 vs 356 
and 358). 
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
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4.1. SUMMARY 
4.1.1. SWR/J MICE ARE SUSCEPTIBLE TO ENU-INDUCED LEUKEMIA 
We treated a cohort of 245 SWR/J mice with the potent mutagen ENU.  This was to 
generate tumors in the mice of the hematopoietic lineages.  We used different permutations of 
steroid to try to reduce the onset of lymphomas.  We were able to determine that SWR/J mice are 
susceptible to ENU-induced leukemia (11.2%).  The steroids did not have any effect on reducing 
the number of lymphomas that occurred.  Overall, this strain will provide an important 
background for studying t-AML and for crossing with other mice that have been genetically 
altered to mimic some aspect of the disease.  This will lead to models that will more closely 
recapitulate the disease and will bring us closer to a therapeutic solution.    
4.1.2. MLF1 INDUCES APOPTOSIS IN HEMATOPOIETIC CELLS 
The work here shows that MLF1 is pro-apoptotic in hematopoietic cells.  When we 
overexpressed MLF1 using the MLF1-ires-YFP retrovirus we were able to show both in the 
Ba/F3 cell line and primary bone marrow cells that MLF1 induced apoptosis and decreased the 
viability of cells.  When we tested the effect of MLF1 using genetically defined mice and treated 
those cells with ENU, again we saw that MLF1 status was important for the apoptotic phenotype 
and for the viability of cells.  C57BL/6J mice of different MLF1 genotypes that were challenged 
by the additional stressor of sub-lethal irradiation showed no difference in recovery rates.  
C57BL/6J mice treated in vivo resulted in wildtype obtaining 3 leukemias in a small cohort 
compared to no leukemias in knockout mice.  This difference in frequency of leukemias may not 
be meaningful, given the small sample size.  This result contradicts our model because instead of 
inducing apoptosis and evading leukemia, the wildtype mice still went on to develop disease.  
70 
Mice lacking MLF1 went on to develop the rapidly developing lymphomas, which may be due to 
the fact that they could not induce apoptosis at as high of rate and thus carried more mutations 
that led to lymphoma and lung cancer development.  
4.2. ONGOING WORK AND FUTURE DIRECTION 
What is the molecular pathway that MLF1 works through? 
 It has been shown that MLF1 has multiple, novel binding partners (MLF1IP, Manp, 
Manp, CS3N, 14-3-3ζ).  One group shows that MLF1 interacts with CS3N which decreases 
levels of COP1 [1].  This leads to increased levels of p53, and eventually cell cycle arrest in 
NIH3T3 cells.  One work in progress was to ask whether MLF1 induced apoptosis was p53-
dependent or independent.  We were in the process of shuttling HA-MLF1 over to pcDNA3.1+ 
vector (Invitrogen).  From there, we were going to transduce HCT116-/- and HCT116+/+ cells 
with the vector.  HCT116-/- cells are p53 knockouts.  Our prediction was that if MLF1 apoptosis 
was dependent on p53, you would not see cell death in the HCT116-/- cells but would still see 
death in the wildtype cells.  
What portion or sequence variant is required for apoptosis? 
 To fully understand MLF1, any functional domains need to be closely mapped out.  We 
started to perform fine-mapping to define the region.  The idea was to transduce cells with the 
mutants and see if any or all of them still induced apoptosis.  If the results were all of them, we 
would continue our fine-mapping strategy in new areas until we found the region responsible for 
apoptosis.  In addition to this, there are point mutations in MLF1 that may influence how much 
apoptosis gets induced.  One of these point mutations is MLF1P226T.  The P variant is found at a 
higher ratio than the T variant.  It is possible that these single point mutations do matter even if 
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they do not change expression levels of the protein they may slightly change the function by 
changing binding partners, altering subcellular localization, etc.    
Alternative strategies to generate Mlf1 transgenic mice?    
We speculate that MLF1 overexpression in male germ cells was toxic, resulting in 
inability to transmit the transgene through the germline.  That is what we suspect happened.  It is 
also possible that the constitutive overexpression of MLF1 is too potent in hematopoietic cells.  
We have already shown that MLF1 increases cell death and decreases viability in Ba/F3 cells.  
Another potential caveat is that a MLF1 transgenic mouse was not viable due to bone marrow 
failure that prevents a mouse from developing.  Future directions would need to address ways to 
circumvent this issue. 
One alternative approach would be to make a conditional mouse using the tetracycline 
responsive system reviewed by Ryding et al. [2].  This system relies on the control tetracycline 
repressor has over the gene of interest.  This happens by binding to the tetracycline operator 
sequences within the promoter.  This results in repressed transcriptional activation.  Adding 
tetracycline binds up all the repressor and turns the gene “on”.  We would need to have two 
transgenics.  One would be the tTA expressing line to cross with the tetO-vav-HA-hMLF1 
mouse.  Tetracycline would be added to turn the gene on once the mouse was fully developed. 
Another approach would be to overexpress MLF1 using a MLF1-ires- YFP-MSCV 
retrovirus.  Bone marrow from C57BL/6J CD45.2 donor mice will be harvested and infected by 
the retrovirus.  Cells will be sorted to enrich for the YFP+ population and 1x106 cells will be 
transplanted into lethally irradiated C57BL/6J CD45.1 recipient mice.  Peripheral blood will be 
obtained via retro orbital eye bleeds one month following transplantation.  FACS will be used to 
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determine percent engraftment (CD45.1 vs CD45.2) and the percentage of YFP+ cells.   Mice 
will be analyzed as described above.   
Another caveat could be that we do not see a phenotype in the transgenic mouse.  This 
would suggest that MLF1 overexpression alone is not sufficient to disrupt normal bone marrow 
function in vivo.  This mouse model would still provide a useful tool for mutagenesis and for 
breeding to other mouse models with genetic disruptions that may cooperate with MLF1 to 
contribute to disease.  
How is SWR/J mice susceptibility to ENU-induced leukemia affected by knocking out 
Mlf1? 
We fully backcrossed the MLF1 null allele into the SWR/J (sensitive) genetic 
background.  Future experiments could test whether MLF1 deficiency converts this sensitive 
strain to a resistant one.  Based on our initial results attempting to convert a resistant strain 
(C57BL/6J) to a sensitive one, large cohort sizes and/or additional sensitizing transgenes (e.g., 
PML/RARA) may be required to test this definitively.
Is the pro-apoptotic effect of MLF1 dependent on stage of differentiation? 
Here we hint that in C57BL/6J mice, the Gr-1+ cells are susceptible to MLF1 induced 
cell death.  In data not shown, we have seen that macrophages are resistant and monocytes are 
the most susceptible to MLF1 induced apoptosis.  On the SWR/J background we show that 
kit+lin- cells are susceptible.  A careful study of both backgrounds needs to be conducted where 
bone marrow will be stained for flow cytometric analysis with antibodies conjugated to B220, 
CD3, CD45, c-Kit, CD11b, Gr-1, ter119, and Dx5.  Cells will also be kit+lin- flow sorted  
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